Genfit (GNFT) Stock Price, News & Analysis

Company Overview

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Key Stats

• Today's Range: $4.24 to $4.36
• 50-Day Range: $2.71 to $4.62
• 52-Week Range: $2.55 to $6.42
• Volume: 23,013 shs
• Average Volume: 15,239 shs
• Market Capitalization: $217.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Genfit Stock Analysis - MarketRank™

Genfit scored higher than 26% of companies evaluated by MarketBeat, and ranked 827th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Genfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genfit has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Genfit are expected to decrease in the coming year, from $0.95 to ($0.57) per share.

Price to Book Value per Share Ratio

Genfit has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.13% of the float of Genfit has been sold short.

Short Interest Ratio / Days to Cover

Genfit has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Genfit has recently increased by 24.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genfit does not currently pay a dividend.

Dividend Growth

Genfit does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.13% of the float of Genfit has been sold short.

Short Interest Ratio / Days to Cover

Genfit has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Genfit has recently increased by 24.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

Genfit has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Genfit this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genfit insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Genfit is held by insiders.

Percentage Held by Institutions

Only 2.24% of the stock of Genfit is held by institutions.

GNFT Stock Analysis - Frequently Asked Questions

How have GNFT shares performed this year?

Genfit's stock was trading at $3.71 on January 1st, 2025. Since then, GNFT shares have increased by 17.5% and is now trading at $4.36.
View the best growth stocks for 2025 here.

When did Genfit IPO?

Genfit (GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival Co. & (CCL).

Company Calendar

• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNFT
• CIK: 1757064
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +208.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $67.00 million
• Price / Sales: 3.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.48 per share
• Price / Book: 2.85

Miscellaneous

• Outstanding Shares: 49,996,000
• Free Float: 47,896,000
• Market Cap: $210.73 million
• Optionable: Not Optionable
• Beta: 0.92